StaffHealth: Polish Code, American Market, Global Ambition

The American startup StaffHealth, powered by a proprietary platform developed in Poland, has secured $6.5 million in funding. Investors — Rubicon Partners, Maciej Zientara, and Wojciech Duda — recognized not only a scalable business model, but also a real solution to one of the most pressing challenges in the U.S. healthcare system. The still-fragmented temporary staffing market, worth billions of dollars, is waiting for a technological leader — and StaffHealth is hungry to take that role.

StaffHealth: A Real Solution to a Growing Problem

StaffHealth is a prime example of a project tackling a real and escalating challenge. On one side, hospitals and healthcare facilities are struggling with staffing shortages. On the other, medical professionals are seeking flexibility and control over their schedules. As investor Wojciech Duda explained in an interview with My Company Polska, addressing both sides of this equation was the key reason behind his decision to invest.

“From our perspective, the most important thing about StaffHealth is that it solves a major problem — access to qualified medical staff for professional facilities, and dynamic shift management. For healthcare workers, it’s an app that lets them browse and choose available shifts and manage their own schedules. For facilities, it enables fast and efficient staffing,” says Wojciech Duda, investor and Vice President of Duda Holding.

Polish Technology Meets American Market Experience

At the heart of StaffHealth is a sophisticated tech platform built in Poland. Business development, however, is led by a U.S.-based team with deep experience in the healthcare staffing industry. Investor Maciej Zientara highlights this geographic diversification as a key factor in his decision to invest.

“We really liked the fact that the technology is developed in Poland — which is both effective and cost-efficient — while the product and market focus is on the massive U.S. healthcare sector. Thanks to the work of CTO Mariusz Nowak, the team built a highly scalable marketplace solution that can handle large volumes of leads in real time. That was the trigger for my belief that this project could offer real technological and cost advantages in a well-established market,” explains Maciej Zientara, investor and managing partner at Supernova Group.

This hybrid model was made possible by the involvement of Rubicon Partners, which acts as a venture builder — not only providing capital but actively participating in company development. Grzegorz Golec, co-founder, co-CEO, and investor in StaffHealth, elaborates on this dual role.

“Rubicon — and myself as project lead — built the Polish side of the business. On the other hand, our U.S. co-founders and partners come from the healthcare staffing industry, with experience dating back to its analog days. We combined their industry knowledge with Polish technology. That mix is proving to be very promising,” says Grzegorz Golec, co-CEO of StaffHealth and managing partner at Rubicon Partners.

Appetite for Growth in a Multi-Billion-Dollar Market

StaffHealth’s potential is best illustrated by the scale of the market it operates in. According to Golec, the U.S. temporary healthcare staffing market is worth around $20 billion and remains highly fragmented. Even the most advanced tech players hold only a small share, creating a major opportunity for new entrants.

“This market is still forming. Consolidation will take time, and anyone participating now has a real chance to secure a leadership position in the next few years. That’s another reason why we believe this investment is so promising,” adds Golec.

CTO Mariusz Nowak adds that over 5 million nurses in the U.S. work in a B2B model, and StaffHealth’s largest competitor has already raised $500 million in funding.

To maintain growth momentum and pursue expansion — including potential acquisitions of traditional staffing agencies — StaffHealth is finalizing a SAFE (Simple Agreement for Future Equity) round of approximately $2.5 million. Previous rounds brought in $4 million from existing investors. The SAFE funds will convert into equity during the next major funding round, expected to reach at least $5 million in late 2025 or early 2026.

Challenges and Risks — From Tech to Scaling

Like any innovative venture, StaffHealth faced early-stage risks. According to Golec, the biggest uncertainty was whether the technology could be successfully launched — a prerequisite for the entire business.

“The biggest risk back then was whether we could get the tech up and running. If we hadn’t, there simply wouldn’t be a business,” admits Golec.

Now that the platform is live and growing at around 10% month-over-month since November last year, the nature of risk has shifted. Zientara points out that the challenge now is maintaining growth speed to stay ahead of market demand.

“I see risk from a different angle now — it’s about keeping pace with the market. As the company grows rapidly, working capital needs will increase. We need more funding to keep up with demand and competition. If the market wants our solution, we need to fuel the engine. That’s why we’re doing the SAFE round,” emphasizes Zientara.

Another challenge for investors is managing a business across continents. That’s why Golec plays a key role as the “bridge between Poland and the U.S.” — overseeing the project on-site and providing confidence to other investors.

Exit Scenarios: M&A, IPO, and Multiples

Investors estimate that StaffHealth’s value could grow five to seven times over the next few years. When asked about their ideal exit, they agree: it will be whoever offers the best price. Still, the most likely scenarios are clearly defined.

“If the company continues its growth path, it will be an attractive target for private equity funds. I also see potential for an IPO. It’s a business that could generate dividends. Of course, there’s also the possibility of a strategic acquisition if we reach sufficient scale — and given the current market dynamics, we expect consolidation appetite from major players,” analyzes Golec.

Zientara is more direct:

“I’m convinced we’ll end up in a classic M&A. Americans love growth through acquisitions. I expect that between year three and four, the company’s value will increase five to seven times — and we’ll be bought.”

Ultimately, the exit will depend on how much value StaffHealth can build in the coming years. But the appetite for growth is clear — and the next funding rounds are set to fuel the journey.

Source: My Company Polska